Savior Lifetec Corporation (TPEX:4167)

Taiwan · Delayed Price · Currency is TWD

19.95

+0.10 (0.50%)

Jun 18, 2026, 1:30 PM CST

-0.50% (1Y)

Market Cap	6.19B -9.0%
Revenue (ttm)	1.17B -4.1%
Net Income	241.59M -51.4%
EPS	0.78 -50.3%
Shares Out	310.44M
PE Ratio	25.70
Forward PE	n/a
Dividend	0.81 (4.04%)
Ex-Dividend Date	Jul 14, 2025

Volume	612,854
Open	20.00
Previous Close	19.85
Day's Range	19.75 - 20.05
52-Week Range	16.45 - 22.60
Beta	0.11
Analysts	Hold
Price Target	23.74 (+19.0%)
Earnings Date	Aug 7, 2026

About Savior Lifetec

Savior Lifetec Corporation, a specialty injectable company, develops, produces, and supplies sterile active pharmaceutical ingredients and finished dosage formulations. The company provides various carbapenem generic drugs and injections, such as paliperidone palmitate, cetrorelix and ganirelix acetate, plecanatide, prucalopride succinate, and brinzolamide. It offers imipenem and cilastatin, meropenem, and ertapenem products. The company was founded in 1993 and is headquartered in Tainan City, Taiwan. [Read more]

Industry Biotechnology

Sector Healthcare

Founded 1993

Employees 384

Stock Exchange Taipei Exchange

Ticker Symbol 4167

Full Company Profile

Financial Performance

In 2025, Savior Lifetec's revenue was 1.20 billion, a decrease of -1.28% compared to the previous year's 1.22 billion. Earnings were 537.45 million, an increase of 194.69%.

Financial Statements